Population-based survival analyses of central nervous system tumors from 1994 to 2008. An up-dated study in the temozolomide-era

Cancer Epidemiology

Volumn 38, Issue 3, 2014, Pages 244-247

  Fuentes Raspall, Rafael ^a,b   Puig Vives, Montserrat ^a,b,c,d   Guerra Prio, Silvia ^a   Perez Bueno, Ferran ^e   Marcos Gragera, Rafael ^a,b,c,d  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c UNIVERSITY OF GIRONA   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Population based study; Primary brain tumors; Survival; Temozolomide

Indexed keywords

TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ADULT; ARTICLE; ASTROCYTIC TUMOR; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHOROID PLEXUS TUMOR; CONTROLLED STUDY; DEATH CERTIFICATE; EMBRYONAL TUMOR; EPENDYMAL TUMOR; FEMALE; FOLLOW UP; GLIOBLASTOMA; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OLIGOASTROCYTIC TUMOR; OLIGODENDROGLIAL TUMOR; POPULATION; PRIORITY JOURNAL; SHORT TERM SURVIVAL; TUMOR DIAGNOSIS; ANALOGS AND DERIVATIVES; CENTRAL NERVOUS SYSTEM NEOPLASMS; EPIDEMIOLOGY; MORTALITY; PROGNOSIS; SPAIN; SURVIVAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; CENTRAL NERVOUS SYSTEM NEOPLASMS; DACARBAZINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SPAIN; SURVIVAL ANALYSIS;

EID: 84900501677     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.03.014     Document Type: Article

References (24)

1. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 2007, 14(August (2)):97-109.
2. Crocetti E., Trama A., Stiller C., Caldarella A., Sofietti R., Jaal J., et al. Epidemiology of glial and non-glial brain tumors in Europe. Eur J Cancer 2012, 48:1532-1542.
3. Baumert B.G., Brada M., Bernier J., Kortmann R.D., Dehing-Oberije C., Collette L., et al. EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm. Radiother Oncol 2008, 88:163-172.
4. Young G.S. Advanced MRI of adult brain tumors. Neurol Clin 2007, 25:947-973.
5. Souhami L., Seiferheld W., Brachman D., Podgorsak E.B., Werner-Wasik M., Lustig R., et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004, 60:853-860.
6. Tsao M.N., Mehta M.P., Whelan T.J., Morris D.E., Hayman J.A., Flickinger J.C., et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 2005, 63:47-55.
7. Walker M.D., Alexander E., Hunt W.E., MacCarty C.S., Mahaley M.S., Mealey J., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 1978, 49:333-343.
8. Wen P.Y., Kesari S. Malignant gliomas in adults. N Engl J Med 2008, 359:492-507.
9. Newlands E.S., O'Reilly S.M., Glaser M.G., Bower M., Evans H., Brock C., et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996, 32A(December (13)):2236-2241.
10. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 5(11):987-996.
11. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J.B., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
12. [accessed July 2013]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
13. Mason W.P., Del Maestro R., Eisenstat D., Forsyth P., Fulton D., Laperreire N., et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol 2007, 14(3):110-111.
14. Johnson D.R., O'Neill B.P. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012, 107:359-364.
15. Darefsky A.S., King J.T., Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 2012, 118:2163-2172.
16. European Network of Cancer Registries, Tyczynski J.E., Démaret E., Parkin D.M., World Health Organization, European Commission International Agency for Research on Cancer. Standards and guidelines for cancer registration in Europe: the ENCR recommendations 2003, vol. I. International Agency for Research on Cancer, Lyon.
17. International Statistical Classification of Disease and Related Health Problems. Tenth revision-ICD-10. Genera, Switzerland 2003.
18. Fuentes-Raspall R., Vilardell L., Perez-Bueno F., Joly C., Garcia-Velasco A., Marcos-Gragera M. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005. J Neurooncol 2011, 101:117-122.
19. Davis F.G., Freels S., Grutsch J., Barlas S., Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998, 88:1-10.
20. van den Bent M.J., Carpentier A.F., Brandes A.A., Sanson M., Taphoorn M.J., Bernsen H.J., et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006, 24(June (18)):2715-2722.
21. Cairncross G., Berkey B., Shaw E., Jenkins R., Scheithauer B., Brachman D., et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006 Jun, 24(18):2707-2714.
22. Fleury A., Menegoz F., Grosclaude P., Daures J.P., Henry-Amar M., Raverdy N., et al. Descriptive epidemiology of Cerebral Gliomas in France. Cancer 1997, 79:1195-1202.
23. Calli C., Kitis O., Yunten N., Yurtseven T., Islekel S., Akalin T. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006, 58(3):394-403.
24. Morita N., Harada M., Otsuka H., Melhem E.R., Nishitani H. Clinical applications of MR spectroscopy and imaging of brain tumor. Magn Reson Med Sci 2010, 9(4):167-175.